Key result
Anticoagulant treatment successfully diminished a left ventricular thrombus that developed as a complication of non-severe COVID-19 in a patient with dilated cardiomyopathy.
Why the study?
Thrombosis, especially venous thromboembolism, is often linked to COVID-19, but there have been relatively few reports of arterial thrombosis.
Case Report (n=1)
No
May warrant vigilance for LV thrombus in DCM with non-severe COVID-19; leaves open need for prospective thromboprophylaxis studies.
Thrombosis, especially venous thromboembolism, is a complication often associated with coronavirus disease 2019 (COVID-19). However, there have been relatively few reports of arterial thrombosis. Here, we describe a case of non-severe COVID-19 in a patient with dilated cardiomyopathy. After admission, symptoms, laboratory data, and imaging findings improved, but D-dimer levels gradually increased. Contrast computed tomography and echocardiography revealed a left ventricular thrombus. Anticoagulant treatment diminished the thrombus, and the patient recovered and was discharged. Although a left ventricular thrombus is a rare COVID-19 complication, performing appropriate diagnostic tests could improve COVID-19 mortality in patients with dilated cardiomyopathy. La thrombose, en particulier la maladie thromboembolique veineuse, est une complication souvent associée à la maladie à coronavirus 2019 (COVID-19). Cependant, il y a eu relativement peu de cas rapportés de thrombose artérielle. Nous décrivons ici un cas non grave de COVID-19 chez un patient atteint de cardiomyopathie dilatée. Après admission, des améliorations ont été constatées concernant les symptômes, les résultats des tests de laboratoire et les résultats d'imagerie, mais les taux de D-dimères ont progressivement augmenté. La tomodensitométrie avec produit de contraste et l'échocardiographie ont révélé un thrombus ventriculaire gauche. Un traitement anticoagulant a réduit le thrombus, et le patient s'est remis et a reçu son congé. Bien qu'un thrombus ventriculaire gauche soit une complication rare de la COVID-19, la réalisation de tests diagnostiques appropriés pourrait diminuer la mortalité due à la COVID-19 chez les patients atteints de cardiomyopathie dilatée.
No takes yet. Share an insight, caveat, or question.
Imaeda et al. (2020) conducted a case report in COVID-19 and Dilated Cardiomyopathy (n=1). Anticoagulation therapy (unfractionated heparin and vitamin-K antagonist) was evaluated on Thrombus resolution. Anticoagulant treatment successfully diminished a left ventricular thrombus that developed as a complication of non-severe COVID-19 in a patient with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: